On November 22, 2022 Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, reported that members of its executive team will host an investor event to provide a data update that will include preliminary data from the six-month follow-up of the first 75 patients enrolled in the IGNYTE clinical trial cohort of RP1 combined with Opdivo in anti-PD1 failed melanoma (Press release, Replimune, NOV 22, 2022, View Source [SID1234624348]). Additionally, the company will review the commercial opportunity in skin cancer with RP1. The Company will also provide an update on its RP2 and RP3 program.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The event will begin at 8:00 a.m. Eastern Time on Wednesday, December 7, 2022. The webcast and slides will be accessible live under "Events & Presentations" on the Investors page of the Company’s website at www.replimune.com or by clicking here. A replay of the event will be available on Replimune’s website.
Opdivo (nivolumab) is a registered trademark of Bristol-Myers Squibb Company.